Flash FinanceUS
Market closed S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Harmony Biosciences Holdings (HRMY)

Harmony Biosciences Q3 WAKIX revenue rises 12% to $269 million; profit falls

Mixed Impact 3 of 5 earnings

Harmony Biosciences reported third-quarter 2026 WAKIX net revenue of $268.9 million, up 12% from $239.5 million a year earlier, and reiterated full-year WAKIX net revenue guidance of $1.0 billion to $1.04 billion. Net income fell to $48.2 million, or $0.81 per diluted share, from $50.9 million, or $0.87, a year earlier, mainly due to higher milestone charges and new royalty charges tied to the Novitium license.

Key points

  • Q3 2026 WAKIX net revenue of $268.9 million, up 12% from $239.5 million in Q3 2025
  • Net income of $48.2 million, or $0.81 per diluted share, versus $50.9 million, or $0.87, in Q3 2025
  • Full-year 2026 WAKIX net revenue guidance of $1.0 billion to $1.04 billion reiterated
  • Peter Anastasiou will succeed Jeffrey Dayno, MD, as President and CEO effective January 1, 2027

The filing

CompanyHarmony Biosciences Holdings (HRMY)
Form8-K, current report
Filed with the SECNov 4, 2026, 8:00 AM ET
Accession number0001104659-26-122377

Items reported: 2.02 Results of Operations7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 7, 2026, 11:17 PM ET, from the text of the filing and its press-release exhibits only.

Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.